41 results about "Bicistronic mrna" patented technology

Compositions and methods relating to microRNA (miRNA) technology are disclosed. In particular, microRNA (miRNA) expression vectors and methods for the treatment of sensory disorders, e.g., for the treatment of hearing loss, are described.

An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.

The invention discloses a dicistronic specific DNA utilizing a lacZ alpha oligopeptide encoding gene as a second gene encoding frame and application of the dicistronic specific DNA in expressing a target gene. A specific DNA molecule provided by the invention has a bicistronic structure, and sequentially comprises the following components from upstream to downstream: a lac promoter, a lac control region, a first ribosome bind site, a gene encoding frame I, a second ribosome bind site, a gene encoding frame II and a terminator; the last nucleotide of the gene encoding frame I is connected with a first nucleotide of the second ribosome bind site; and the gene encoding frame II encodes lacZ alph oligopeptide formed by the first to nth amino acid residues from the N terminal of lacZ, wherein n is a natural number within a range of 50-150. The specific DNA molecule provided by the invention has dual capabilities of judging whether an extraneous target gene in the gene encoding frame I is expressed or not and judging the expression amount of extraneous target genes by directly observing without special steps, and has great application value.

The present invention relates to the production of structural proteins and virus-like particles (VLPs) of flaviviruses and hepatitis C. Production is through use of a single expression cassette comprising a viral structural gene, a furin encoding gene and a bicistronic expression element such as an internal ribosome entry site (IRES) between the viral and furin genes. Both the viral gene and furin gene can include a partial capsid encoding sequence acting as a signal peptide to co-locate the viral protein and furin and to act as a membrane anchor for the viral protein and furin. A separate expression cassette comprising a non-structural viral gene can be combined with the initial cassette. The structural proteins and VLPs can be used in vaccines and in the treatment of viral infections.

The present invention discloses a series of eukaryotic expression vectors utilizing the reduction of transcription read-through events to create stable and high-yield cell lines for recombinant protein expression. The vectors comprise more than one polyadenylation signal or one or more polyadenylation signals plus other DNA fragment which is known to enhance transcription termination to control the expression level of selection marker, with the configuration to transcribe the minimal level of full-length bicistronic mRNA to express the selection marker, which can be used to create stable cell lines at high expression levels, without the need for drug selection or drug mediated gene amplification.

The present invention relates to a bicistronic expression vector for silencing a gene specifically in astrocytes and neurons, comprising two expression cassettes comprising a first and a second silencer sequence, respectively, wherein the expression of said first silencer sequence within astrocytes is regulated by an astrocyte-specific promoter and the expression of said second silencer sequence within neurons is regulated by a neuron-specific promoter. In a preferred embodiment, said first and second silencer sequences are SOD1 silencer sequences. Pharmaceutical composition comprising said bicistronic vector and the use of the same in the treatment of motoneuron diseases are further described.

The present invention relates to a bicistronic expression vector for silencing a gene specifically in astrocytes and neurons, comprising two expression cassettes comprising a first and a second silencer sequence, respectively, wherein the expression of said first silencer sequence within astrocytes is regulated by an astrocyte-specific promoter and the expression of said second silencer sequence within neurons is regulated by a neuron-specific promoter. In a preferred embodiment, said first and second silencer sequences are SOD1 silencer sequences. Pharmaceutical composition comprising said bicistronic vector and the use of the same in the treatment of motoneuron diseases are further described.

The invention discloses a Bcl2 mutant capable of promoting larger gene expression and its application. The Bcl2 mutant of the present invention is that the 190th codon of the mouse Bcl2 gene is mutated from GGA to a stop codon TGA, or the 193rd codon of the human Bcl2 gene is mutated from GGA to a stop codon TGA. In the present invention, by mutating the 568th base (the 577th position of the human Bcl2 gene), G is changed to T, and the mutated phosphorylated Bcl2 and the objective recombinant protein gene are constructed on a bicistronic expression vector. Promote the expression of the target recombinant protein gene larger than 4.3kb.

The invention relates to a macrobrachium rosenbergii bicistronic messenger ribonucleic acid (mRNA) viral genome complete sequence and an application thereof, which belong to the technical field of virus genomics. The invention provides the macrobrachium rosenbergii bicistronic mRNA viral genome complete sequence shown as SEQIDNO: 1. In addition, the invention provides a macrobrachium rosenbergii bicistronic mRNA viral specific primer, a probe or a reagent kit. The macrobrachium rosenbergii bicistronic mRNA viral genome complete sequence and the application lay the reliable foundation to the purposes of macrobrachium rosenbergii dicistrovirus (MRDV) detection, MRDV infection path study and the like.

The invention provides a bicistronic DNA vaccine for grouper viral neuronecrosis, which is a recombinant eukaryotic expression vector, and the recombinant eukaryotic expression vector can simultaneously express the P-domain of neuronecrosis virus capsid protein and the superfamily domain of the grouper interferon regulatory factor 3 protein. The anti-necrosis virus bicistronic DNA vaccine prepared by the invention can well express the neuronecrosis virus capsid protein P-domain and the superfamily domain of the host's interferon regulatory factor 3 protein when transfected into fish. The prepared anti-neuronecrosis virus bicistronic DNA vaccine enhances the ability of fish to resist nerve necrosis virus infection, reduces the mortality rate of fish infected with the virus, enhances the humoral immunity of fish caused by the vaccine, and causes fish body The comprehensive immune response provides a good immune protection effect for the fish body.

The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria E. coli. The present invention also provides the process for the expression of protein of interest using said bicistronic vector.

The invention relates to a virus construct for treating liver cancer and an application and construction method of the virus construct. The invention also relates to a novel oncolytic virus for individualized targeted treatment on liver cancer and a construction method thereof. The construct of the present invention comprises an AFP promoter, an RGD-4C gene, an IL-12-p40 gene, an IRES gene, an IL-12-p35 gene, and optionally a glutamyl transpeptidase gene and a tumor-associated antigen gene in an effective ligation manner.

This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.

The invention discloses a dicistronic specific DNA utilizing a lacZ alpha oligopeptide encoding gene as a second gene encoding frame and application of the dicistronic specific DNA in expressing a target gene. A specific DNA molecule provided by the invention has a bicistronic structure, and sequentially comprises the following components from upstream to downstream: a lac promoter, a lac control region, a first ribosome bind site, a gene encoding frame I, a second ribosome bind site, a gene encoding frame II and a terminator; the last nucleotide of the gene encoding frame I is connected with a first nucleotide of the second ribosome bind site; and the gene encoding frame II encodes lacZ alph oligopeptide formed by the first to nth amino acid residues from the N terminal of lacZ, wherein n is a natural number within a range of 50-150. The specific DNA molecule provided by the invention has dual capabilities of judging whether an extraneous target gene in the gene encoding frame I is expressed or not and judging the expression amount of extraneous target genes by directly observing without special steps, and has great application value.

The invention relates to construction and application of an IRES (Internal Ribosome Entry Site) mediated four GH (Growth Hormone) subtypes and IGF-I (Insulin-like Growth Factor I) bicistronic eukaryon co-expression vector. The construction comprises the following steps of: obtaining coding sequence design primers of four GH subtypes and the IGF-I by the comparison of the mRNA sequence and the protein sequence of the GH and the IGF-I; obtaining a target DNA of the four GH subtypes and the IGF-I through a PCR (Polymerase Chain Reaction) method by taking the DNA of the GH and the IGF-I in a laboratory as a template; connecting a PCR product to a pBS-T vector to obtain TA vectors of the GH and the IGF-I; carrying out XhO I and EcoR I double enzyme digestion on the TA vector and directionally inserting genes of the four GH subtypes into the pCI-IRES to successfully construct recombinant plasmids of the four GH subtypes: pCI-22-IRES, pCI-20-IRES, pCI-17-IRES and pCI-5-IRES; and carrying out Sam I and Not I double enzyme digestion on the TA vector of the IGF-I and respectively and directionally inserting genes of the IGF-I into such recombinant plasmids to successfully construct the IRES mediated four human GH subtypes and IGF-I bicistronic eukaryon co-expression vector: pCI-22-IRES-IGF-I, pCI-20-IRES-IGF-I, pCI-17-IRES-IGF-I and pCI-5-IRES-IGF-I. The invention provides convenient and efficient basic data for further studying biological characteristics and functions of the four GH subtypes and the IGF-I gene.

The invention discloses a primer group for detecting the reovirus and bicistronic virus of scylla serrata, comprising a reovirus forward primer ReoF, a reovirus reverse primer ReoR, a bicistronic virus forward primer DicF and a bicistronic virus reverse primer DicR, wherein each primer is specifically as follows: ReoF: 5-ACTCATAGAGCAGTCATGGG-3; ReoR: 5-ATATCGTCAGAATGTCGTTC-3; DicF: 5-GGATACTATGGATGATGTTTC-3; and DicR: 5-ACAAAATACCAGATAAAGCAA-3. The invention further discloses a kit containing the primer group and a detection method. The primer group, the kit and the detection method are shortin detection time, strong in specificity, high in detection sensitivity, and capable of simultaneously detecting the reovirus and bicistronic virus of scylla serrata.